Research Article

Pyrrosia petiolosa Extract Ameliorates Ethylene Glycol-Induced Urolithiasis in Rats by Inhibiting Oxidative Stress and Inflammatory Response

Fangmin Zhou1 and Xingshan Wang2

1Department of Pharmacy, The People’s Hospital of Shouguang, Shouguang, Shandong 262700, China
2Department of Urology, The People’s Hospital of Shouguang, Shouguang, Shandong 262700, China

Correspondence should be addressed to Fangmin Zhou; fmzhou001@126.com

Received 30 May 2022; Revised 13 July 2022; Accepted 19 July 2022; Published 5 August 2022

Academic Editor: Gerhard Schmalz

Copyright © 2022 Fangmin Zhou and Xingshan Wang. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To study the therapeutic effect and mechanism of Pyrrosia petiolosa (P. petiolosa) extract on ethylene glycol- (EG-) induced urolithiasis in rats. Methods. Thirty SD male rats were randomly divided into five groups (n = 6): control group, EG group, and P. petiolosa group (25 mg/kg, 50 mg/kg group, and 100 mg/kg). Biochemical testing was adopted for measuring the blood and urine parameters, as well as the level of superoxide dismutase (SOD), glutathione (GSH), and malondialdehyde acid (MDA) in kidney tissues. HE staining and ELISA were utilized to observe the histopathological changes and detect the level of IL-1β, IL-6, MCP-1, and TNF-α in the kidney tissue, respectively. And western blot was performed for checking NOX2, NOX4, TGF-β1, p-Smad3, Smad3, p-Smad2, and Smad2 protein expression level in kidney tissues. Results. EG could significantly increase the level of blood urea nitrogen, creatinine, and Na in serum and 24-hour urinary protein, oxalate, uric acid, creatinine, calcium, and phosphorus in urine and decreased the urine volume in rats. Whereas P. petiolosa extract was able to greatly decrease the level of related parameters in serum and urine in a dose-dependent manner, but did not affect the urine pH. In addition, P. petiolosa extract notably ameliorated EG-induced renal tissue injury. Compared with the EG group, P. petiolosa extract markedly raised the level of SOD and GSH and decreased the MDA level and the expression of NOX2 and NOX4 in the kidney tissue. Moreover, P. petiolosa extract also lowered the level of IL-1β, IL-6, MCP-1, and TNF-α in EG-stimulated kidney tissue and inhibited the protein level of EG-induced TGF-β1, p-Smad3, and p-Smad2 in a concentration-dependent manner. Conclusion. P. petiolosa extract can improve EG-induced urolithiasis in rats by inhibiting oxidative stress, inflammatory response, and the activation of TGF-β pathway.

1. Introduction

Urolithiasis is a complex multifactorial disease caused by the interaction between environmental and genetic factors. Besides, urolithiasis, also known as the formation of urinary stones, is a health problem affecting almost all populations worldwide. Specifically, urolithiasis can result in severe acute back pain and sometimes even induce more severe complications such as pyelonephritis or acute renal failure. Kidney stone formation is a common urological problem with a lifetime prevalence of about 10% in men and 6% in women; its incidence in many developed countries is growing [1–4], and the recurrence rate also approaches 60% within 10 years [5]. At present, drugs for the treatment of urolithiasis in clinical practice mainly include three categories: drugs to dissolve stones or prevent stones enlargement, drugs to relieve renal colic, and drugs to promote stone expulsion. However, these drugs are not widely used due to their side effects. Therefore, there is an urgent need to find new therapeutic agents.

The aggregation of stones in the kidney will continuously stimulate glomerular endothelial cells, mesangial cells, and renal tubular epithelial cells, activate the inflammatory reaction and oxidative stress reaction in the cells, and then cause damage to renal function oxygen free radicals. Inflammatory
proteins/factors and inflammatory reaction can cause membrane damage of renal tubular epithelial cells, improve the adhesion and affinity between calcium salt crystals and cell membrane, and promote the aggregation, nucleation, and growth of calcium salt crystals, which may play an important role in the initial stage of renal stone formation [6, 7]. The TGF-β signaling pathway is an ubiquitous signal transduction pathway in cells, which is involved in the processes of diabetes, hypertension, ischemia-reperfusion injury, and so on. TGF-β pathway is a common pathway in the pathological process of various kidney injuries. Calcium oxalate (CaOx) can activate TGF-β1 induces epithelial mesenchymal transition (EMT) in renal tubular epithelial cells and then promotes the occurrence of renal fibrosis [8]. Therefore, TGF-β signaling pathway can be used as a possible target for drug therapy of renal injury.

Pyrrrosia petiolosa (P. petiolosa), polypodiaceae, is mainly distributed in warm regions of the southeast and northern China as well as provinces of the southern Yangtze River [9]. Studies on chemical constituents and pharmacological effects at home and abroad have demonstrated that the principal active components of P. petiolosa are polysaccharides, flavonoids, triterpenoids, volatile oils, and polyphenols, with antioxidant, diuretic, and kidney-protecting effects. Generally speaking, P. petiolosa is mainly applied in the clinical treatment of nephritis, lung heat cough, gonorrhea, and urinary retention [10]. It has been indicated that there are effective compounds with diuretic potential in the 95% ethanol extract of P. petiolosa [11], and the diuretic parts are petroleum ether and dichloromethane [12]. Apart from that, ethanol extract of P. petiolosa also has good antioxidant [13] and anti-inflammatory activity [14]. However, there are few studies on the treatment of urolithiasis with P. petiolosa. Consequently, this study is intended to investigate the protective mechanism of P. petiolosa extract on EG-induced urolithiasis by establishing an EG-induced urolithiasis model in rats. The purpose of this study was to provide a theoretical basis for the clinical treatment of urolithiasis.

2. Materials and Methods

2.1. Experimental Animals. A total of 30 healthy SD male rats (SPF grade), weighing 180-220 g, were housed in the environment with 50% relative humidity, 12 h light/dark cycle and the temperature of 22°C, which was bought from Guangdong Medical Experimental Center. And subsequent experiments were performed after 7-day adaptive feeding. The animal experiments in this study were authorized by the Experimental Animal Ethics Committee of Guangdong Medical Experimental Center (C202206-02).

2.2. Preparation of P. petiolosa Extract. First, 20 kg P. petiolosa was pulverized into powder. 95% ethanol was applied for 7-day cold soaking for extraction. The cold soaking was repeated three times, and the obtained extracts were mixed and concentrated under reduced pressure. After the alcohol was removed, about 2.3 kg of extracts were collected. Subsequently, the collected extracts were treated by petroleum ether, and the treated extracts were obtained after the solvent was recycled and the petroleum ether was concentrated and volatilized [15].

2.3. Urolithiasis Rat Model Construction and Drug Treatment. The rats were randomly divided into five groups (n = 6): control group, ethylene glycol (EG) group, P. petiolosa-25 mg/kg group, P. petiolosa-50 mg/kg group, and P. petiolosa-100 mg/kg group. In the control group, rats received a normal diet and routine water intake. In the other groups, rats were first given drinking water containing 1% EG to construct the urolithiasis model. After continuously 4-week feeding, rats were gavaged with 25 mg/kg, 50 mg/kg, and 100 mg/kg of P. petiolosa, respectively, and the administration lasted for 4 weeks. At the last treatment, 24 hours of urine was collected from the rats as well as the blood from the abdominal aorta. Afterwards, the rats were sacrificed, and the renal tissues were collected.

2.4. Detection of Biochemical Indicators. The instruction of the kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) was strictly followed for the detection of the biochemical indicators. And the detected indicators included the level of blood urea nitrogen (BUN), creatinine (creatinine in the serum, SCR), and natrium (Na) in rat serum; the level of 24-hour urinary protein (24-up), oxalate, uric acid, Cr, calcium, and phosphorus in rat urine; and the level of superoxide dismutase (SOD), glutathione (GSH), and malondialdehyde acid (MDA) in rat kidneys. Besides, urine pH value and 24-hour urine volume in rats were recorded.

2.5. HE Staining. Kidney tissues were fixed with 4% paraformaldehyde for 48 h, then dehydrated via graded alcohol. Later, the tissues were embedded with paraffin and sectioned at 4 μm. After the sections were air-dried at ambient temperature, they were fixed for 30 s, washed with PBS for 2 s, and stained with hematoxylin (60°C) for 60 s. Next, the sections were washed with PBS for 10 s, then added with 1% hydrochloric acid alcohol differentiation solution for 3 s, washed by PBS for 2 s, stained with eosin for 3 min, and washed again with PBS for 2 s. Subsequently, the sections were dehydrated with 70%, 80%, 95%, and absolute ethanol for 5 min and cleared with xylene 3 times/5 min. Finally, transparent sealing sections with gum were utilized to observe the pathological changes of kidney tissues under a light microscope.

2.6. Enzyme-Linked Immunosorbent Assay (ELISA). ELISA kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) were adopted to detect the expression level of interleukin- (IL-) 1β, IL-6, Monocyte chemoattractant protein-1 (MCP-1), and tumour necrosis factor- (TNF-) α in the kidney tissues of rats, and the detection was operated strictly according to the kit instructions.

2.7. Western Blot. Western blot procedures were performed in reference to the method described by Si et al. [16]. The tissues were lysed by RIPA lystate then centrifuged at 12,000 rpm for 15 min at 4°C to collect supernatant proteins. After detection of protein concentration by BCA reagent (Thermo Fisher, Waltham, MA, USA), 5× loading was
added for preparing protein samples. The proteins were separated by SDS-PAGE and transferred to PVDF membranes. Then, 5% skimmed milk was added for blocking 1 h. Next, antibodies NADPH oxidases 2 (NOX2), NOX4, TGF-β1, p-Smad3, Smad3, p-Smad2, and Smad2 (Proteintech, Chicago, USA) were added, respectively, and the incubation was performed overnight at 4°C in a shaker. Subsequently, the corresponding secondary antibodies were added for another 2 h incubation in the incubator. After washing with tris-buffered saline with Tween (TBST) for 3 times, high-sensitivity luminescence solution was added, the proteins were developed in a chemiluminescence instrument, and the protein gray values were counted utilizing Image J software.

2.8. Statistical Analysis. All data was analyzed by SPSS 26.0 statistical software. A t-test was applied to analyze the comparison between the two groups, one-way analysis of variance was employed for pairwise comparison between multiple groups, and the results were expressed as mean ± standard deviation (SD). P < 0.05 was considered as a significant difference.

3. Results

3.1. Pyrrosia petiolosa Extract Can Significantly Improve Urinary and Serum Parameters in Rats with Ethylene Glycol-Induced Urolithiasis. First of all, the therapeutic effect of P. petiolosa extract on urolithiasis rats was studied. The results displayed that, compared with the control group, EG group exhibited a significant increase in the level of BUN, SCr, and Na in serum, and 24-up, oxalate, uric acid, Cr, calcium, and phosphorus in urine while a marked decrease in urinary output in EG rats. However, in comparison with the EG group, the P. petiolosa-25 mg/kg, P. petiolosa-50 mg/kg, and P. petiolosa-100 mg/kg groups showed a notable reduction in the level of BUN, SCr, and Na in the serum and 24-up, oxalate, uric acid, Cr, calcium, and phosphorus in the urine while a noticeable increase in the urinary output in a concentration-dependent manner. In addition, urine pH value was slightly higher in the EG group than that in the control, P. petiolosa-25 mg/kg, P. petiolosa-50 mg/kg, and P. petiolosa-100 mg/kg groups; however, the difference was not statistically significant (Figures 1(a)–1(k)).

3.2. Pyrrosia petiolosa Extract Could Significantly Ameliorate Ethylene Glycol-Induced Renal Tissue Injury in Rats. The effect of P. petiolosa extract on kidney tissue in urolithiasis rats was further examined. Based on the examination results, the renal tissue of rats in the control group revealed normal renal structure, and no or only a particularly small amount of CaOx crystal deposition was observed. Whereas in the EG group, significant renal histological changes were observed: glomerular edema, vascular congestion, tubular dilatation, epithelial cell degeneration and necrosis, shedding, inflammatory cell infiltration, and CaOx crystal depositions at the junction of renal cortex and medulla. After treatment of rats with P. petiolosa, the renal structure was improved in a dose-dependent manner: tubular dilatation, reduction of vascular congestion, and inflammatory cell infiltration as well as significant decrease of crystal deposition in renal tissue (Figure 2).

3.3. Pyrrosia petiolosa Extract Can Greatly Inhibit Ethylene Glycol-Induced Oxidative Stress in Kidney Tissue of Urolithiasis Rats. Further exploration on mechanism of P. petiolosa extract in treating rats with urolithiasis was conducted. The results revealed an obvious decrease in SOD and GSH, while there was an obvious increase in the MDA level in the EG group compared to the control group; nevertheless, after treatment with P. petiolosa extract, SOD and GSH level were notably upregulated, and MDA level was lowered in rat kidney tissue (Figures 3(a)–3(c)) and indicated that the treatment of urolithiasis rats with P. petiolosa extract may be related to the inhibition of oxidative stress. Further western blot results also demonstrated that the expression of oxidative stress-related proteins NOX2 and NOX4 was remarkably increased, while P. petiolosa extract could markedly inhibited their expression in a dose-dependent manner (Figure 3(d)).

3.4. Pyrrosia petiolosa Extract Can Greatly Suppress the Level of Renal Inflammation in EG-Induced Urolithiasis Rats. The effect of P. petiolosa extract on the inflammatory level in rats with urolithiasis was further determined. According to the outcomes, a great increase in the level of IL-1β, IL-6, MCP-1, and TNF-α in the kidney tissue of rats was observed in the EG group in comparison with that in the control group; however, after treatment with different doses of P. petiolosa, the level of IL-1β, IL-6, MCP-1, and TNF-α in rat kidney tissues was significantly declined in a concentration-dependent manner (Figures 4(a)–4(d)).

3.5. Pyrrosia petiolosa Extract Can Inhibit Activation of TGF-β Pathway in Renal Tissue of Ethylene Glycol-Induced Urolithiasis Rats. Further investigation on the effect of P. petiolosa extract on TGF-β pathway in urolithiasis rats was carried out. Compared with the control group, the TGF-β pathway-related proteins TGF-β1, p-Smad3, and p-Smad2 were evidently on the rise as well as p-Smad3/Smad3 and p-Smad2/Smad2 in the kidney tissue of rats in the EG group, while Smad3 and Smad2 proteins showed few changes. After treatment with P. petiolosa extract, the ratios of TGF-β1, p-Smad3, and p-Smad2 proteins, and p-Smad3/Smad3 and p-Smad2/Smad2 are significantly lowered in tissues (Figure 5).

4. Discussion

Urinary calculi, commonly known as urolithiasis, is a growth and development process of calcification of hard nonmetallic minerals formed in the urinary system [17]. Current drugs for the treatment of urolithiasis are accompanied by various side effects, so it is urgent to seek new drugs. P. petiolosa is a traditional Chinese medicine with the effect of promoting diuresis and relieving stranguria [18], but the therapeutic effect on urolithiasis is unknown. The urinary stone model is an important method [19] to research stone formation and prevention [14]. The urolithiasis rat model of renal calcium oxalate can be effectively established in a
Figure 1: Continued.
**Figure 1:** Effect of Pyrrosia petiolosa extract on blood and urine parameters in ethylene glycol-induced urolithiasis in rats. (a–c) Biochemical detection for the level of blood urea nitrogen (BUN), creatinine (SCr), and natrium (Na) in the serum of rats in each group, respectively. (d–i) Biochemical detection of the level of 24-hour urinary protein (24-up), oxalate, uric acid, Cr, calcium, and phosphorus in the urine of rats in each group, respectively. (j) pH value detection in the urine of rats in each group. (k) The record of 24-hour urine volume of rats; **P < 0.01 vs. control group; #P < 0.05, ##P < 0.01 vs. EG group.
short period of time by feeding drinking water containing 1% EG for 4 weeks. On the basis of this model, it was found that P. petiolosa extract had a diuretic effect and could increase urine volume. The increase in urine volume facilitates the excretion of CaOx crystals in renal tissue and reduces urine saturation. On the one hand, increased urine can wash the kidney, and on the other hand, it can also avoid the formation or retention of crystals. BUN, 24-up, and Cr are commonly used indicators to evaluate renal function and can indicate the degree of renal impairment [20]. The results of this experiment manifested that P. petiolosa extract treatment could significantly reduce the level of BUN, Scr, and Na in serum, and the level of oxalate, uric acid, Cr, calcium, and phosphorus in urine; while notably increasing the urine volume. Besides, P. petiolosa extract treatment also increased urine volume, protected renal function, and reduced renal injury. However, in this study, the therapeutic effect of low dose P. petiolosa seems to be better, which may be because for intragastric administration, the absorption site is usually in the small intestine. As the dose increases, the drug absorption will reach saturation, and then the drug concentration will increase and the blood drug concentration will not increase. All in all, the above findings indicate the functions of P. petiolosa extract in renal function protection and renal injury reduction.

According to previous reports, rats with EG-induced renal calculi will suffer systemic reactive oxygen species (ROS) increase, and increased ROS is accumulated in the renal tissue through the blood circulation; and antioxidant substances with appropriate amount in the organism can work for redox balance [21]. SOD, an endogenous superoxide dismutase produced by the body, can scavenge free radicals and excessive ROS, and the level of SOD can reflect the body’s ability to resist oxidative stress. Antioxidant substances are consumed and reduced because they play a neutralization role when ROS increases in the body. Nonetheless, excessive ROS increase can result in redox imbalance, then cause cytotoxicity and lipid envelope peroxidation, and finally induce the production of MDA [22]. MDA is a product of fatty acid peroxidation in cells, and its content can reflect the degree of cellular peroxidation in the body [23]. In this study, we found a marked rise in the level of SOD and GSH in tissues while a remarkable reduction in MDA level and CaOx crystals after intervention with P. petiolosa extract. The above indicated that P. petiolosa extract may inhibit the internal peroxidation and regulate and restore the redox balance in vivo by increasing exogenous antioxidant substances and neutralizing excessive ROS in rats; and by this, P. petiolosa extract could reduce lipid peroxidation and then inhibit the formation of stones. This conclusion is similar to the results of previous studies. Numerous macrophage accumulations have been reported to occur in rat models of kidney stones, suggesting that inflammatory factors released by macrophages may be associated with the formation of CaOx crystals [24]. Urine supersaturation promotes kidney damage by inducing the production of reactive oxygen species and oxidative stress, and the subsequent inflammatory immune response promotes Randall’s plaque formation and calcium stone formation [25]. In this study, the level of IL-1β, IL-6, MCP-1, and TNF-α in kidney tissue was significantly reduced after intervention with P. petiolosa extract; and it could be concluded that P. petiolosa extract had a role in anti-inflammation.

As a recent study showed, oxidative stress and ROS may be one of the mechanisms of urolithiasis development [26]. NADPH oxidase, one of the important sources of intracellular ROS, has been discovered a total of seven subtypes so far. And according to different catalytic subunits, the subtypes are divided into Nox1, Nox2, Nox3, Nox4, Nox5, Duox1, and Duox2 [27, 28]. To be specific, NADPH oxidase is distributed in a variety of cells in the kidney, and Nox2 and Nox4 are the major subtype expressions [27, 28]. Some researchers have revealed that NADPH oxidase is the main source of ROS in the kidney, especially in the presence of angiotensin II [29]. Normally, the activity of NADPH oxidase in the kidney is very weak, just producing a small amount of ROS to involve in the body’s defense response, cell proliferation, cell apoptosis, cell signal transduction, and other processes. When the kidney is stimulated by exogenous microorganisms, lipopolysaccharides, and some other factors, renal cells undergo a respiratory burst and produce large amounts of ROS for host defense [30]. In vivo animal experiments have confirmed that the abnormal activation of NADPH oxidase is involved in the process of kidney stone formation [31]. Candesartan, losartan, atorvastatin, and other antihypertensive and lipid regulating drugs can inhibit
Figure 3: Effect of Pyrrosia petiolosa extract on oxidative stress in renal tissue of ethylene glycol-induced urolithiasis in rats. (a–c) Biochemical detection for the level of SOD, GSH, and MDA in the kidneys of rats in each group, respectively. (d) Western blot detection of NOX2 and NOX4 protein expression level in the kidney tissues of rats in each group (n = 3). **P < 0.01 vs. control group; #P < 0.05, ##P < 0.01 vs. EG group.
the formation of renal calcium oxalate stones by inhibiting the production of ROS mediated by NADPH oxidase [32, 33]. When the antioxidant capacity of the body is insufficient, excessive ROS will cause an inflammatory response and injury in the kidney [34]. Detection of the level of Nox2 and Nox4 was chosen to reflect the renal NADPH oxidase expression in this study. The results also revealed that the protein level of NOX2 and NOX4 in rat kidney tissues was greatly reduced after treatment with P. petiolosa extract.

As a profibrotic cytokine, TGF-β1 signals via Smad-dependent and Smad-independent pathways and leads to a variety of downstream biological effects [35, 36]. Therefore, TGF-β1-Smad signaling pathway is the most important pathway in progressive renal fibrosis, and in renal calculi patients and animal models, Smad2 and Smad3 are widely activated in fibrotic kidneys [37]. Related reports have pointed out that the TGFB/Smad signaling pathway is activated in the glyoxalate-induced crystalline kidney injury model in mice and then results in occurrence of EMT and fibrosis [38, 39]. The damage of oxalic acid to renal tubular cells and its stone promoting effect is mainly caused by oxalic acid in cells. NADPH oxidase is affected by regulation of TGF-β1 [40]. Hong et al. [41] confirmed the blocking of any stage of TGF-β1-NAPDH-ROS pathway can inhibit the production of ROS. Therefore, TGF-β1-NAPDH-ROS pathway is the main pathway of ROS production induced by oxalic acid. In this study, noticeable decreases were discovered in both the protein level of TGF-β1, p-Smad3, and p-Smad2 and the ratios of p-Smad3/Smad3 and p-Smad2/Smad2 in the kidney tissue after treatment with P. petiolosa extract. The above findings indicated that P. petiolosa extract could inhibit TGF-β1/Smad signaling pathway in the kidney of urolithiasis rats, thereby improving EG-induced renal injury in urolithiasis rats.

![Figure 4: Effect of Pyrrosia petiolosa extract on the level of renal tissue inflammation in ethylene glycol-induced urolithiasis in rats. (a–d) ELISA was adopted to detect the level of IL-1β, IL-6, MCP-1, and TNF-α in the kidney tissue of rats in each group, respectively. **P < 0.01 vs. control group; *P < 0.05, ##P < 0.01 vs. EG group.](image-url)
5. Conclusion

In summary, P. petiolosa extract is effective in treating kidney injury in EG-induced urolithiasis rats. And the mechanism may be achieved by inhibiting oxidative stress, alleviating inflammatory response, and suppressing the activation of TGF-β pathway. Still, further exploration is needed for the validation and improvement of other possible pathways involved in the protection of renal tissue by P. petiolosa extract in urolithiasis rats. After that, we can provide a more comprehensive explanation of the mechanism of P. petiolosa extract in the treatment of urolithiasis rats and a new therapeutic direction for clinical application.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Ethical Approval

The animal experiments described in this study were authorized by Experimental animal ethics committee of Guangdong Medical Experimental Center (GME-2022011).

Conflicts of Interest

The authors declare that they have no competing interests.

Authors’ Contributions

Fangmin Zhou and Xingshan Wang contributed equally to this work as co-first author.

References

[1] T. Yasui, M. Iguchi, S. Suzuki, and K. Kohri, “Prevalence and epidemiological characteristics of urolithiasis in Japan: national trends between 1965 and 2005,” Urology, vol. 71, no. 2, pp. 209–213, 2008.

[2] K. K. Stamatelou, M. E. Francis, C. A. Jones, L. M. Nyberg, and G. C. Curhan, “Time trends in reported prevalence of kidney stones in the United States: 1976-1994,” Kidney International, vol. 63, no. 5, pp. 1817–1823, 2003.

[3] A. Hesse, E. Brandle, D. Wilbert, K. U. Kohrmann, and P. Alken, “Study on the prevalence and incidence of urolithiasis in Germany comparing the years 1979 vs. 2000,” European Urology, vol. 44, no. 6, pp. 709–713, 2003.

[4] A. Trinchieri, F. Coppi, E. Montanari, A. del Nero, G. Zanetti, and E. Pisani, “Increase in the prevalence of symptomatic upper urinary tract stones during the last ten years,” European Urology, vol. 37, no. 1, pp. 23–25, 2000.

[5] W. L. Strohmaier, “Course of calcium stone disease without treatment. What can we expect?,” European Urology, vol. 37, no. 3, pp. 339–344, 2000.

[6] A. Y. Sun, B. Hinck, B. R. Cohen, K. Keslar, R. L. Fairchild, and M. Monga, "Inflammatory cytokines in the papillary tips and urine of nephrolithiasis patients," Journal of Endourology, vol. 32, no. 3, pp. 236–244, 2018.
[7] G. B. Stefano, S. Challenger, and R. M. Kream, “Hyperglycemia-associated alterations in cellular signaling and dysregulated mitochondrial bioenergetics in human metabolic disorders,” European Journal of Nutrition, vol. 55, no. 8, pp. 2339–2345, 2016.

[8] R. Kanlaya, K. Sintiprungrat, and V. Thongboonkerd, “Secreted products of macrophages exposed to calcium oxalate crystals induce epithelial mesenchymal transition of renal tubular cells via RhoA-dependent TGF-β1 pathway,” Cell Biochemistry and Biophysics, vol. 67, no. 3, pp. 1207–1215, 2013.

[9] J. L. Yang, Q. M. Guo, F. Q. Zhou, Z. X. Chen, and J. X. Li, “Microscopic identification of P. petiola and its closely related leaves,” Journal of Chinese Medicinal Materials, vol. 32, no. 7, pp. 1046–1048, 2009.

[10] X. Qi, L. Li, and Y. Y. Zhang, “Research advance in chemical and pharmacological on Pyrrosia petiola (Christ) ching,” Shandong Chemical Industry, vol. 47, no. 16, pp. 64–65, 2018.

[11] T. Q. Lang, Y. Zhang, F. Chen, G. Y. Luo, and W. D. Yang, “Characterization of chemical components with diuretic potential from Pyrrosia petiola,” Journal of Asian Natural Products Research, vol. 23, no. 8, pp. 764–771, 2021.

[12] F. Chen, G. Y. Luo, and W. D. Yang, “Chemical constituents from promoting diuresis and relieving stranguria effective part of Pyrrosia petiola in Guizhou,” Journal of Chinese Medicinal Materials, vol. 42, no. 12, pp. 2822–2826, 2019.

[13] C. Y. Hsu, “Antioxidant activity of Pyrrosia petiola,” Fitoterapia, vol. 79, no. 1, pp. 64–66, 2008.

[14] D. Cheng, Y. Zhang, D. Gao, and H. Zhang, “Antibacterial and anti-inflammatory activities of extract and fractions from Pyrrosia petiola (Christ et Bar.) ching,” Journal of Ethnopharmacology, vol. 155, no. 2, pp. 1300–1305, 2014.

[15] Y. Hu, F. Chen, Y. Long et al., “Chemical constituents from promoting diuresis and relieving stranguria effective part of Pyrrosia petiola in Guizhou (II),” Journal of Chinese Medicinal Materials, no. 6, pp. 1384–1389, 2021.

[16] Y. Si, L. Liu, J. Cheng et al., “Oral hydrogen-rich water alleviates oxalate-induced kidney injury by suppressing oxidative stress, inflammation, and fibrosis,” Frontiers in Medicine, vol. 8, p. 713536, 2021.

[17] R. Dighade, R. Ingole, P. Ingle, A. Gade, and M. Ingawale, “Nephroprotective effect of bryophyllum pinnatum-mediated silver nanoparticles in ethylene glycol-induced urolithiasis in rat, IET Nanobiotechnology,” vol. 15, no. 3, pp. 266–276, 2021.

[18] Y. R. Wang and W. D. Yang, “Preliminary study on diuresis of Pyrrosia petiola from Guizhou Province extracts in rats,” Lishizhen Medicine and Materia Medica Research, vol. 28, no. 11, pp. 2583–2585, 2017.

[19] X. R. Li, Z. J. Yue, W. Pei et al., “Comparison of four renal calcium oxalate calculus rat models,” Journal of Modern Urology, vol. 18, no. 4, pp. 329–331, 2013.

[20] O. W. Moc, “Kidney stones: pathophysiology and medical management,” Lancet, vol. 367, no. 9507, pp. 333–344, 2006.

[21] S. Thamilselvan, K. J. Byer, R. L. Hackett, and S. R. Khan, “Free radical scavengers, catalase and superoxide dismutase provide protection from oxalate-associated injury to LLC-PK1 and MDCK cells,” The Journal of Urology, vol. 164, no. 1, pp. 224–229, 2000.

[22] Y. Sato, S. Kajiyama, A. Amano et al., “Hydrogen-rich pure water prevents superoxide formation in brain slices of vitamin C-depleted SMP30/GNL knockout mice,” Biochemical and Biophysical Research Communications, vol. 375, no. 3, pp. 346–350, 2008.

[23] S. Roy, P. Sable, A. Khair, K. Randhir, A. Kale, and S. Joshi, “Effect of maternal micronutrients (folic acid and vitamin B12) and omega 3 fatty acids on indices of brain oxidative stress in the offspring,” Brain and Development, vol. 36, no. 3, pp. 219–227, 2014.

[24] R. Kanlaya, K. Sintiprungrat, S. Chaibarit, and V. Thongboonkerd, “Macropinocytosis is the major mechanism for endocytosis of calcium oxalate crystals into renal tubular cells,” Cell Biochemistry and Biophysics, vol. 67, no. 3, pp. 1171–1179, 2013.

[25] S. R. Khan, B. K. Canales, and P. R. Dominguez-Gutierrez, “Randall’s plaque and calcium oxalate stone formation: role for immunity and inflammation,” Nature Reviews. Nephrology, vol. 17, no. 6, pp. 417–433, 2021.

[26] G. Vezzoli, A. Terraneo, T. Arcidiacono et al., “Calcium kidney stones are associated with a haplotype of the calcium-sensing receptor gene regulatory region,” Nephrology, Dialysis, Transplantation, vol. 25, no. 7, pp. 2245–2252, 2010.

[27] F. Jiang, Y. Zhang, and G. J. Dusting, “NADPH oxidase-mediated redox signaling: roles in cellular stress response, stress tolerance, and tissue repair,” Pharmacological Reviews, vol. 63, no. 1, pp. 218–242, 2011.

[28] M. Sedeek, R. Nasrallah, R. M. Touyz, and R. L. Hebert, “NADPH oxidases, reactive oxygen species, and the kidney: friend and foe,” Journal of the American Society of Nephrology, vol. 24, no. 10, pp. 1512–1518, 2013.

[29] S. R. Khan, “Reactive oxygen species, inflammation and calcium oxalate nephrolithiasis,” Translational Andrology and Urology, vol. 3, no. 3, pp. 256–276, 2014.

[30] S. Chen, X. F. Meng, and C. Zhang, “Role of NADPH oxidase-mediated reactive oxygen species in podocyte injury,” BioMed Research International, vol. 2013, Article ID 839761, 7 pages, 2013.

[31] J. Zuo, A. Khan, P. A. Glenton, and S. R. Khan, “Effect of NADPH oxidase inhibition on the expression of kidney injury molecule and calcium oxalate crystal deposition in hydroxy-L-proline-induced hyperoxaluria in the male Sprague-Dawley rats,” Nephrology, Dialysis, Transplantation, vol. 26, no. 6, pp. 1785–1796, 2011.

[32] I. Yoshioka, M. Tsujihata, W. Akanae, N. Nonomura, and A. Okuyama, “Angiotensin type-1 receptor blocker candesartan inhibits calcium oxalate crystal deposition in ethylene glycol-treated rat kidneys,” Urology, vol. 77, no. 4, pp. 1007.e9–1007.e14, 2011.

[33] B. Qin, Q. Wang, Y. Lu et al., “Losartan ameliorates calcium oxalate-induced elevation of stone-related proteins in renal tubular cells by inhibiting NADPH oxidase and oxidative stress,” Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 1271864, 12 pages, 2018.

[34] X. Wang, Q. Wu, A. Liu et al., “Paracetamol: overdose-induced oxidative stress toxicity, metabolism, and protective effects of various compounds in vivo and in vitro,” Drug Metabolism Reviews, vol. 49, no. 4, pp. 395–437, 2017.

[35] I. Loeffler and G. Wolf, “Transforming growth factor- and the progression of renal disease,” Nephrology Dialysis Transplantation, vol. 29, supplement 1, pp. 137–145, 2014.

[36] Q. Chen, H. Guo, J. Hu, and X. Zhao, “Rhein inhibits NF-kappaB signaling pathway to alleviate inflammatory response and oxidative stress of rats with chronic glomerulonephritis,”
[37] X. M. Meng, A. C. Chung, and H. Y. Lan, “Role of the TGF-β/I
BMP-7/Smad pathways in renal diseases,” Clinical Science (London, England), vol. 124, no. 4, pp. 243–254, 2013.

[38] W. R. Liu, H. T. Lu, T. T. Zhao et al., “Fu-Fang-Jin-Qian-Cao
herbal granules protect against the calcium oxalate-induced
renal EMT by inhibiting the TGF-β/smad pathway,” Pharmaceutical Biology, vol. 58, no. 1, pp. 1115–1122, 2020.

[39] K. Sharma, “Obesity, oxidative stress, and fibrosis in chronic
kidney disease,” Kidney International Supplements, vol. 4,
o. 1, article S2157171615312041, pp. 113–117, 2014.

[40] S. Piera-Velazquez, A. Makul, and S. A. Jiménez, “Increased
expression of NAPDH oxidase 4 in systemic sclerosis dermal
fibroblasts: regulation by transforming growth factor β,” Arthritis & Rheumatology, vol. 67, no. 10, pp. 2749–2758, 2015.

[41] S. H. Hong, H. J. Lee, E. J. Sohn et al., “Anti-nephrolithic
potential of resveratrol via inhibition of ROS, MCP-1, hyaluronan and osteopontin in vitro and in vivo,” Pharmacological Reports, vol. 65, no. 4, pp. 970–979, 2013.